SLC5A2 and dementia: Among 106,903 individuals, SGLT-2 inhibitors were associated with a decreased risk of dementia (14.2/1000 person-years; aHR 0.80 [95% CI 0.71–0.89]) when compared with DPP-4 inhibitors.